FDA Approves First Treatment for Adult Onset Still’s Disease, a Severe and Rare Disease
WASHINGTON, D.C. — The U.S. Food and Drug Administration approved Ilaris (canakinumab) injection for the treatment of Active Still’s disease, including Adult-Onset Still’s Disease (AOSD). Ilaris was previously approved for …
Read More